From an interesting 2020 study paper from Taiwan [1].
"ADT was associated with a 17-22% risk reduction in all-cause and PC-specific mortality in men without stroke, CAD {coronary arterial disease}, or CHF {congestive heart failure} in the 65-79-year group.
"The survival benefit diminished in men with any of these preexisting conditions.
"In contrast, ADT was not found to be associated with any survival benefit in the ≥80-year group, even though they did not present with any major cardiovascular disease at the baseline.
"Patients who had CHF, CAD, or stroke at the baseline did not show a survival benefit following ADT in any of the age groups.
"Men who have preexisting major cardiovascular diseases or are ≥80 years do not demonstrate a survival benefit from ADT for mPC. The risk-benefit ratio should be considered when using ADT for mPC in older men especially those with major cardiovascular comorbidities."
-Patrick
[1] pubmed.ncbi.nlm.nih.gov/319...
Full text: ncbi.nlm.nih.gov/pmc/articl...
Cancers (Basel)
. 2020 Jan 12;12(1):189. doi: 10.3390/cancers12010189.
Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
Szu-Yuan Wu 1 2 3 4 , Su-Chen Fang 5 , Olivia Rachel Hwang 6 , Hung-Jen Shih 7 8 , Yu-Hsuan Joni Shao 6 9
Affiliations collapse
Affiliations
1 Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung 413, Taiwan.
2 Division of Radiation Oncology, Department of Medicine, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 265, Taiwan.
3 Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 265, Taiwan.
4 Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung 413, Taiwan.
5 Department of Nursing, Mackay Medical College, New Taipei City 252, Taiwan.
6 Department, Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei 110, Taiwan.
7 Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei 106, Taiwan.
8 Department of Urology, School of Medicine, Taipei Medical University, Taipei 110, Taiwan.
9 Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan.
PMID: 31940958 PMCID: PMC7016583 DOI: 10.3390/cancers12010189
Free PMC article
Abstract
Few studies have assessed the benefits of androgen deprivation therapy (ADT) in men with metastatic prostate cancer (PC; mPC) at an old age or with major cardiovascular conditions. A retrospective cohort consisted of 3835 men with newly diagnosed mPC from the Taiwan Cancer Registry of 2008-2014. Among them, 2692 patients received only ADT in the first year after the cancer diagnosis, and 1143 patients were on watchful waiting. The inverse probability of treatment-weighted Cox model was used to estimate the effects of ADT on all-cause mortality and PC-specific mortality according to age, and the status of congestive heart failure (CHF), coronary arterial diseases (CADs), and stroke at the baseline. After a median follow-up of 2.65 years, 1650 men had died. ADT was associated with a 17-22% risk reduction in all-cause and PC-specific mortality in men without stroke, CAD, or CHF in the 65-79-year group. The survival benefit diminished in men with any of these preexisting conditions. In contrast, ADT was not found to be associated with any survival benefit in the ≥80-year group, even though they did not present with any major cardiovascular disease at the baseline. Patients who had CHF, CAD, or stroke at the baseline did not show a survival benefit following ADT in any of the age groups. Men who have preexisting major cardiovascular diseases or are ≥80 years do not demonstrate a survival benefit from ADT for mPC. The risk-benefit ratio should be considered when using ADT for mPC in older men especially those with major cardiovascular comorbidities.
Keywords: age; androgen deprivation therapy; cardiovascular diseases; prostate cancer; survival.